重组凝血因子IX-白蛋白融合蛋白在一期凝血试验中的性能表现
该多中心国际实地研究评估重组凝血因子IX-白蛋白融合蛋白(rIX-FP)在一期凝血(OSC)试验中的检测性能,发现多数商业APTT试剂可准确测定其活性,但Actin FS或高岭土类试剂会约低估50%。
要点
- 多数商业OSC试剂可准确测定rIX-FP活性,与中心实验室结果可比。
- 使用Actin FS或高岭土类APTT试剂时,rIX-FP活性被一致低估约50%。
- rIX-FP在OSC试验中的试剂依赖性变异与未修饰rFIX及rFIXFc相当。
核心结论
- 使用多数商业试剂的OSC试验可准确测定rIX-FP活性,而Actin FS或高岭土类试剂可能导致约50%的活性低估。
研究设计与样本
- 多中心国际实地研究,将rIX-FP加入FIX缺乏血浆,在中心实验室和当地实验室用多种商业OSC APTT试剂检测FIX:C。
- 对临床样本进行配对样本分析,比较当地与中心实验室的FIX:C值。
- 采用加标样本进行内部生物分析研究,比较rIX-FP与未修饰rFIX及rFIX Fc融合蛋白(rFIXFc)的APTT试剂依赖性变异。
主要发现
- 来自10个国家21个参与中心的中心和当地FIX:C评估结果,在18种不同APTT试剂中的大多数与中心实验室结果可比。
- 使用Actin FS或高岭土类APTT试剂的OSC试验中,rIX-FP活性被一致低估约50%。
- 在生物分析研究中,rIX-FP在OSC试验中的变异性与未修饰rFIX和rFIXFc相当。
关键数值与推荐
- 使用Actin FS或高岭土类APTT试剂时,rIX-FP活性在OSC试验中低估约50%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials Performance of the one-stage clotting (OSC) assay varies with the clotting activator used. Recombinant FIX-albumin fusion protein (rIX-FP) was reliably monitored with most OSC reagents. rIX-FP shows comparable reagent-dependent variability to other rFIX products in the OSC assay. Actin® FS and kaolin-based reagents underestimated rIX-FP activity by around 50% in the OSC assay. SUMMARY: Background Measuring factor IX activity (FIX:C) with one-stage clotting (OSC) assays, based on the activated partial thromboplastin time (APTT), is the current mainstay of diagnostic techniques for hemophilia B. Assessing the performance of new recombinant FIX (rFIX) products in OSC assays is essential, as APTT reagents from different manufacturers yield different potency estimates for rFIX. Objectives To evaluate the extent to which choice of reagent composition influences rFIX potency measurements of recombinant FIX-albumin fusion protein (rIX-FP, IDELVION) activity in OSC assays. Methods rIX-FP was added to FIX-deficient plasma, and FIX:C was assessed centrally and locally in a multicenter international field study with a variety of commercial OSC APTT reagents. Paired sample analysis of clinical samples was performed to compare values of FIX:C from local and central laboratories. In-house bioanalytical investigations with spiked samples were conducted to compare the APTT-reagent dependent variability of rIX-FP with unmodified rFIX and rFIX Fc fusion protein (rFIXFc). Results Central and local assessments of FIX:C from 10 countries and 21 participating centers showed comparable results to those from the central laboratory across the majority of 18 different APTT reagents from both clinical and spiked samples. There was a consistent underestimation of rIX-FP activity of ≈ 50% with OSC assays using Actin FS or kaolin-based APTT reagents. In the bioanalytical study, rIX-FP showed comparable variability in OSC assays to unmodified rFIX and rFIXFc. Conclusions rIX-FP activity can be accurately measured by the use of OSC assays with the majority of commercial reagents. Actin FS or kaolin-based reagents will probably lead to a 50% underestimation of activity.
引用
- Horn C, Négrier C, Kalina U, et al. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays. J Thromb Haemost. 2018. PMID: 30418692. doi:10.1111/jth.14332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。